Committees

International Organising Committee

Symposium Chairman

R. MOREIRA

University of Lisbon, Lisbon, Portugal

Members

B. CLEMENT

University of Kiel, Kiel, Germany

G. COSTANTINO

University of Parma, Parma, Italy

P. JONES

University of Dundee, Glasgow, United Kingdom

H. P. MAERKI

F. Hoffmann-La Roche, Basel, Switzerland

E. OTTOW

Bayer HealthCare, Berlin, Germany

A. M. SILVA

University of Aveiro, Aveiro, Portugal

K. B. SIMONSEN

Lundbeck, San Diego, United States

H. U. STILZ

Novo Nordisk, Cambridge, United States

H. TIMMERMAN

VU University Amsterdam, Oegstgeest, The Netherlands

Local Organising Committee

Members

J. CAVALEIRO

University of Aveiro, Aveiro, Portugal

P. S. DA SILVA

Bial Ltd, S. Mamede do Coronado, Portugal

W. HEGGIE

Hovione, Loures, Portugal

A. M. LOBO

New University of Lisbon - FCT, Caparica, Portugal

M. MARQUES

Instituto Superior Técnico, ULisboa, Lisboa, Portugal

R. MOREIRA

University of Lisbon, Lisbon, Portugal

M. PINTO

Faculty of Pharmacy, University of Porto, Porto, Portugal

F. PROENÇA

University of Minho, Braga, Portugal

C. ROMAO

Alfama & ITQB, Oeiras, Portugal

M. L. SA E MELO

University of Coimbra, Coimbra, Portugal

A. M. SILVA

University of Aveiro, Aveiro, Portugal

S. SIMOES

Bluepharma & University of Coimbra, Coimbra, Portugal

International Scientific Committee

Members

K.-H. ALTMANN

SCS DMCCB & Swiss Federal Institute of Technology, Zürich, Switzerland

P. ARTURSSON

Uppsala University, Uppsala, Sweden

Y. P. AUBERSON

Novartis Institutes for BioMedical Research, Basel, Switzerland

S. BAGAL

Pfizer Neusentis, Cambridge, United Kingdom

B. BANG-ANDERSEN

H. Lundbeck A/S, Valby, Denmark

E. BANOGLU

Gazi University, Ankara, Turkey

E. BARREIRO

Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

M.-J. BLANCO

Cambridge, MA, United States

M. BRANDS

Bayer Pharma AG, Wuppertal, Germany

A. BROWN

Pfizer Neusentis, Deal, United Kingdom

M. J. CAMARASA

IQM-CSIC, Madrid, Spain

N. CARRUTHERS

Johnson & Johnson R&D, San Diego, United States

G. CIRRINCIONE

University of Palermo, Palermo, Italy

S. CONWAY

University of Oxford, Los Angeles, United States

B. COX

Novartis Institutes for Biomedical Research, Brighton, United Kingdom

P. S. DA SILVA

Bial Ltd, S. Mamede do Coronado, Portugal

A. DAVIS

AstraZeneca, Mölndal, Sweden

G. DUBURS

Latvian Institute of Organic synthesis, Riga, Latvia

G. ECKER

University of Vienna, Vienna, Austria

P. ETTMAYER

Boehringer Ingelheim, Vienna, Austria

E. FERREIRA

University of Sao Paulo, Sao Paulo, Brazil

V. GABELICA MARKOVIC

Fidelta Ltd, Zagreb, Croatia

C. GARCIA-ECHEVERRIA

Sanofi, Vitry sur Seine, France

C. GENICOT

UCB Biopharma, Brussels, Belgium

P. GEORGE

SCT & Independent Scientific Expert & Adviser, Longvilliers, France

M. HANN

GSK Medicines Research Centre, Stevenage, United Kingdom

R. HARTMANN

Saarland University, Saarbrücken, Germany

T. HOFFMANN

F. Hoffmann-La Roche, Basel, Switzerland

T. HÖGBERG

Leo Pharma, Ballerup, Denmark

A. P. IJZERMAN

Leiden University, Leiden, The Netherlands

H. JHOTI

Astex Therapeutics, Cambridge, United Kingdom

K. JOZWIAK

Medical University of Lublin, Lublin, Poland

G. KESERU

Hungarian Academy of Sciences, Budapest, Hungary

G. KLEBE

Philipps-University Marburg, Marburg, Germany

A. KOUROUNAKIS

University of Athens, Athens, Greece

A. LEVITZKI

Hebrew University of Jerusalem, Jerusalem, Israel

J. MACK

Boehringer Ingelheim, Biberach an der Riss, Germany

M. MARQUES

Instituto Superior Técnico, ULisboa, Lisboa, Portugal

L. MEERPOEL

Janssen R&D, Belgium

J. MESTRES

IMIM and University Pompeu Fabra, Girona, Spain

F. MICHELI

Aptuit, Verona, Italy

J. MINERS

Flinders University School of Medicine, Bedford Park, Australia

M. MISSBACH

Novartis, Basel, Switzerland

C. MONTANARI

University of Sao Paulo, Sao Paulo, Brazil

G. MUELLER

Mercachem, Basel, Germany

R. NUDELMAN

Teva Pharmaceutical Industries, Petah Tikva, Israel

D. OLIVER

North-West University, Potchefstroom, South Africa

T. OOST

Boehringer Ingelheim, Biberach, Germany

V. A. PALYULIN

Lomonosov Moscow State University, Moscow, Russia

Z. PAN

Peking University, Shenzhen, China

L. PETERLIN MASIC

University of Ljubljana, Ljubljana, Slovenia

M. PINTO

Faculty of Pharmacy, University of Porto, Porto, Portugal

A. T. PLOWRIGHT

AstraZeneca, Cambridge, United Kingdom

J. ROBERTSON

TES Pharma S.r.l., Corciano , Italy

I. ROZAS

Trinity College Dublin, Dublin, Ireland

G. SCHNEIDER

ETH Zürich, Zurich, Switzerland

N. SHIMMA

SynGen Consulting, Kanagawa, Japan

S. SIMOES

Bluepharma & University of Coimbra, Coimbra, Portugal

H. STEINHAGEN

Grünenthal, Verona, Italy

H. SUGA

University of Tokyo, Tokyo, Japan

G. TAMAGNAN

Institute for Neurodegenerative Disorders and Molecular NeuroImaging, LLC, New Haven, United States

A. THOMAS

F. Hoffmann-La Roche Ltd, Basel, Switzerland

A. TORRENS

Esteve Pharmaceuticals, Barcelona, Spain

M. TOZER

Peakdale Molecular, Bognor Regis, United Kingdom

A. TSANTILI-KAKOULIDOU

University of Athens, Athens, Greece

K. URBAHNS

Merck KGaA, Darmstadt, Germany

S. VAN CALENBERGH

UGent, Ghent, Belgium

M. VARASI

European Institute of Oncology, Milano, Italy

G. L. VERDINE

Harvard University, Cambridge, United States

P. WARNER

Formerly with AstraZeneca, United Kingdom

A. WILLIAMS

Eli Lilly and Co Ltd, Reading, United Kingdom

A. WOOD

Pfizer, Stevenage, Herts, SG1 2NY, United Kingdom

J. YLI-KAUHALUOMA

University of Helsinki, Helsinki, Finland

A. YONATH

Weizmann Institute of Science, Rehovot, Israel

M.-Q. ZHANG

Amgen China, Shanghai, China